NCT07532746 2026-04-16
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
Phase 1 Not yet recruiting
Clinical Trials
12 trialsNCT07254793 2026-04-07
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Phase 1 Not yet recruiting
NCT07485504 2026-03-20
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1 Not yet recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07316907 2026-01-05
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07294300 2025-12-19
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06345027 2025-12-16
CASEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07255898 2025-12-01
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06528249 2024-07-30
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
Zhejiang Provincial People's Hospital
Phase 1 Not yet recruiting
NCT06211751 2024-01-18
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT05391490 2022-05-26
KCAT19
University College, London
Phase 1 Not yet recruiting